PMID: 9663614Jul 15, 1998Paper

In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: a SCID mouse model

International Journal of Cancer. Journal International Du Cancer
A C StenholmJ Zeuthen

Abstract

Tumor-specific T cells may be induced in vitro and in vivo. A tumor, however, is able to avoid recognition by T cells by various mechanisms, and it has therefore been difficult to use these cells for the treatment of cancer. To investigate these mechanisms, it would be desirable to identify a suitable in vivo model system to avoid the ethical considerations that are obviously limiting factors for studies in humans. In addition, tumor antigens, although recognized, may not always function as rejection antigens, thus, the establishment of an in vivo model is crucial for preclinical studies to allow the characterization of effective rejection antigens. We show here that the immunodeficient scid mouse is an excellent model system. Using this system, we demonstrate that an already established human melanoma tumor is eradicated by an in vitro generated autologous cytotoxic T cell clone.

References

Mar 6, 1991·Journal of the National Cancer Institute·J J MuléS A Rosenberg
May 1, 1990·Scientific American·S A Rosenberg
Jul 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·R AbonourV Malkovska
May 1, 1997·Biochemical Society Transactions·P G CoulieT Boon
Jan 1, 1997·International Journal of Clinical & Laboratory Research·B J Van den Eynde, T Boon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.